The Week Ahead: Hom...
Health Care: Drugs
United Therapeutics Corporation (UTHR: NASDAQ)
$69.17 0.69 | 1.01%
05/17/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 69.17 |
| 52 Week High | 69.21 |
| 52 Week Low | 41.75 |
| Avg. Daily Vol. (Mil) | 0.84 |
| Beta (3 year) | 1.41 |
| Share Related Items | |
| Mkt Cap (Mil) | 3,435.68 |
| Shares Out (Mil) | 49.71 |
| Float (Mil) | 42.45 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 4.40 |
| Current Ratio | 4.80 |
| LT Debt/ Equity | 0.24 |
| Total Debt / Equity | 0.24 |
| Valuation Ratios | |
| Price Earnings | 12.40 |
| Price/Sales | 3.59 |
| Price/Book | 2.99 |
| Price/Cash Flow | 10.10 |
| Per Share Data | |
| Earnings | 5.59 |
| Sales | 19.25 |
| Book Value | 23.15 |
| Cash Flow | 6.85 |
| Business Summary | |
|---|---|
| United Therapeutics Corporation is a biotechnology company, which is focused on the development and commercialization of products to address the medical needs of patients with chronic and life-threatening conditions. | |
| General Information | |
| 1040 Spring Street
Silver Spring, MD 20910 |
|
| www.unither.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 623 | |
| CEO: Martine A. Rothblatt,PhD | |
| Short Interest | |
| Current Month (Mil) | 7.21 |
| Previous Month (Mil) | 6.94 |
| Short Interest Ratio (Days) | 8.60 |
| Management Effectiveness | |
| Return on Equity | 25.70 |
| Return on Assets | 17.40 |
| Return on Investments | 20.70 |
| Profitability | |
| Gross Margin | 91.60 |
| EBIT Margin | 46.50 |
| Profit Margin | 30.90 |
Portfolios with UTHR
- Portfolio NameUser Type
- ProJoel Greenblatt - Gotham Ca...
- ContributorDrugs Facing FDA Approval i...
- UserBender
- ContributorStocks With Big Insider Buy...
- ContributorHot Biotech Stocks Traded b...
- Contributor8 Health Care Stocks Inside...
- ContributorStocks With Big Insider Buy...
- Contributor5 Biotech Stocks for 2012
- Contributor5 Low PEG / Low Beta Stocks
- Contributor13 Biotech Stocks Bought an...
Latest UTHR Headlines from TheStreet
- United Stock Hits New 52-Week High (UTHR) 05.14.13 | 02:05 pm
- Leaders of TheStreet's Drug Approval Contest 05.06.13 | 09:05 am
- United Rises On Unusually High Volume (UTHR) 04.30.13 | 04:04 pm
- United Stock Hits New 52-Week High (UTHR) 04.24.13 | 02:04 pm
- The Next Big Thing In Biotech: Decision Week
03.21.13 | 09:03 am - United Reaches New 52-Week High (UTHR) 03.20.13 | 01:03 pm
- United Reaches New 52-Week High (UTHR) 03.12.13 | 03:03 pm
- Best And Worst FDA Drug Approval Stocks of 2013 03.12.13 | 08:03 am
- Programmed Insider Buying? Yes, at Insmed and United Therapeutics 01.24.13 | 08:01 am
- 5 Stocks Insiders are Buying This Week 12.26.12 | 12:12 pm
Press Releases for UTHR
- United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013 - PR Newswire 04.18.13 | 06:04 am
- United Therapeutics Announces Receipt Of Second Complete Response Letter For Oral Treprostinil NDA - PR Newswire 03.25.13 | 05:03 am
- United Therapeutics Corporation To Announce Fourth Quarter And Annual 2012 Financial Results Before Market Open On Tuesday, February 26, 2013 - PR Newswire 02.19.13 | 06:02 am
- United Therapeutics Announces FDA Acceptance Of Resubmission Of Oral Treprostinil NDA - PR Newswire 02.14.13 | 06:02 am
- United Therapeutics Announces Additional $420 Million Share Repurchase Program - PR Newswire 02.04.13 | 06:02 am
- United Therapeutics Corporation To Announce Third Quarter 2012 Financial Results Before Market Open On Thursday, November 1, 2012 - PR Newswire 10.25.12 | 06:10 am
- United Therapeutics Announces Receipt Of Complete Response Letter For Oral Treprostinil NDA - PR Newswire 10.23.12 | 04:10 pm
- United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable Treprostinil For Pulmonary Arterial Hypertension - PR Newswire 09.20.12 | 06:09 am
- United Therapeutics Corporation To Announce Second Quarter 2012 Financial Results Before Market Open On Thursday, July 26, 2012 - PR Newswire 07.19.12 | 06:07 am
- United Therapeutics Announces Additional $100 Million Share Repurchase Program - PR Newswire 06.27.12 | 06:06 am
Partner Headlines for UTHR
- United Therapeutics Holds 10-Week Despite FDA Setback - Investor's Business Daily 04.08.13 | 05:04 pm
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy - Seeking Alpha 03.28.13 | 09:03 am
- United Therapeutics Shows Why Buying Early Is Risky - Investor's Business Daily 03.25.13 | 05:03 pm
- Stocks End Lower After Notching Multiyear Highs - Investor's Business Daily 03.25.13 | 04:03 pm
- Stocks Lower In Early Afternoon; United Health Slumps - Investor's Business Daily 03.25.13 | 01:03 pm
- Futures Up On Cyprus Bailout; ARM Holdings, Dell, Apollo Rise - Investor's Business Daily 03.25.13 | 09:03 am
- Here's What To Look For In A 'Going Nowhere' Market - Investor's Business Daily 03.22.13 | 05:03 pm
- United Therapeutics Near Top Of Strong Industry Group - Investor's Business Daily 03.15.13 | 05:03 pm
- Biotech Watch-List: Medicine Co., Alkermes, Celgene - Investor's Business Daily 03.11.13 | 05:03 pm
- Medicines Co. In Buy Area As Medical Stocks Hold Up - Investor's Business Daily 02.28.13 | 05:02 pm
